

Preliminary to examination of this application, please amend the application as follows:

In the Specification

1. On page 1, please replace the paragraph beginning at line 31, with the following paragraph:

A1
This is a divisional application of United States patent application no. 09/352,308 filed July 12, 1999 and issued October 9, 2001 as U.S. Patent 6,300,332, which claims priority to United States patent application 08/887,312 filed July 3, 1997, which is a continuation-in-part of United States patent application no. 08/658,726, filed June 5, 1996. The disclosures of the following applications are hereby incorporated herein by reference in their entirety: United States patent application no. 08/658,726 filed June 5, 1996; United States patent application no. 08/169,879 filed December 17, 1993; United States patent application no. 08/098,333 filed July 30, 1993; United States patent application no. 08/430,677 filed April 28, 1995; International Patent Application no. PCT/GB93/00216 filed February 2, 1993; Great Britain patent application 9202238.3 filed 3 February 1992; and all applications from which they claim priority, or from which priority is claimed.

Amend the claims as follows:

Cancel claims 1-46 in the original application.

Add new claims 47-75, as follows:

47. A pharmaceutical composition comprising:

- A2
- (1) an effective amount of a bioactive compound mediating respiratory depression, muscle rigidity, and/or nausea/vomiting as an unwanted side effect thereof; and
 - (2) a non-polypeptide δ receptor activating agent effective for combating said side effect.

48. The pharmaceutical composition of claim 47, wherein the δ receptor activating agent comprises a diarylmethylpiperazine or a diarylmethylpiperazine compound.